SkinBioTherapeutics PLC Initiation of oral health development programme (6495W)
April 27 2021 - 2:00AM
UK Regulatory
TIDMSBTX
RNS Number : 6495W
SkinBioTherapeutics PLC
27 April 2021
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
SkinBioTherapeutics initiates new oral health development
programme
in partnership with the University of Manchester
Manchester, 27 April 2021 - SkinBioTherapeutics plc (AIM: SBTX),
a life science company focused on the microbiome, announces that it
has initiated a research and development programme in oral health
with the University of Manchester ("the University"), as discussed
when the Company executed its Placing in October 2020.
The oral health programme will explore the use of different
bacteria, including SkinBioTherapeutics' proprietary lysate,
SkinBiotix(R), for oral health and well-being. The programme will
be led by Professor Andrew McBain
and Dr Ruth Ledder from the School of Health Sciences at the University of Manchester.
The 12-month programme will develop and test formulations
designed to support the health of skin surfaces in
the oral cavity targeting disease prevention, oral care and hygiene.
Good oral health is an essential part of general health and
well-being. The epithelia, or 'skin', surfaces within the oral
cavity are considered gatekeepers that play a critical role in
protection. These surfaces operate both as a physical and
biological barrier, that react to harmful external stimuli by
triggering protective and repair responses. Supporting this skin
layer of cells to respond and to remain healthy not only helps
support oral health but also plays an important role in oral and
systemic disease prevention.
Management believes that focusing on the health of the cells
within the oral cavity is a potentially innovative approach to
developing a suite of oral healthcare formulations. These
formulations could be positioned as standalone products or could
work synergistically with traditional oral health and wellbeing
products.
The global market for oral care was $30.9 billion USD in 2019
and is forecast to reach $38.89 billion by 2027 (Fortune business
insights).
Stuart Ashman, CEO of SkinBioTherapeutics, said:
"This new oral health programme builds and expands on our work
in skin health and applies our already substantial skin microbiome
expertise to the global oral care marketplace. This new strand to
our development portfolio also presents near term
opportunities.
"We believe there is significant potential in oral care for
innovative natural products with anti-microbial characteristics
that can build long lasting protection against disease. This is an
exciting new step for us."
Prof Cath O'Neill, CSO of SkinBioTherapeutics said:
"Our work on the skin's epithelial barrier, the immune system
and the role and importance of the microbiome in health and disease
naturally extends into the other important environmental barriers
such as those in the oral cavity. It is well understood that the
epithelial surfaces in the oral cavity play vital roles in
protecting us from disease. By investigating how our technology can
be applied to support the health of the oral epithelia, we hope to
demonstrate its potential in oral healthcare and disease
prevention."
-Ends-
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014 and has been arranged for
release by Doug Quinn, CFO of the Company. Upon the publication of
this announcement, this inside information is now considered to be
in the public domain.
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161
Stuart J . Ashman, CEO 468 2760
Doug Quinn, CFO
Cenkos Securities Plc (Nominated Adviser Tel: +44 (0) 20 7397
& Broker) 8900
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson (Sales)
Instinctif Partners Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Phillip Marriage 2020
/ Nathan Billis SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Prof. Catherine
O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that
the SkinBiotix(R) platform can improve the barrier effect of skin
models, protect from infection and repair wounds. Proof of
principle studies have also shown that the SkinBiotix(R) platform
has beneficial attributes applicable to each of these areas. The
technology achieved positive results in clinical studies in human
volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in
Manchester, UK. For more information,
visit: www.skinbiotix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGZGZDGVRGMZZ
(END) Dow Jones Newswires
April 27, 2021 02:00 ET (06:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2023 to Apr 2024